Zelluna ASA Logo

Zelluna ASA

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Zelluna ASA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 12:00
Report Publication Announcement
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
English 1.7 KB
2025-07-03 12:07
Share Issue/Capital Change
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
English 3.4 KB
2025-06-25 16:19
Major Shareholding Notification
Disclosure of share transfer from Inven2 AS
English 711 bytes
2025-05-27 13:51
Major Shareholding Notification
Disclosure of Shareholding - Gjelsten Holding AS
English 1.2 KB
2025-05-27 13:38
Share Issue/Capital Change
ZLNA - New registered share capital
English 1.9 KB
2025-05-24 06:37
Share Issue/Capital Change
ZLNA - Issuance of shares through set-off of option exercise fee
English 2.3 KB
2025-05-08 05:00
Investor Presentation
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 1.3 MB
2025-05-08 05:00
Quarterly Report
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 664.4 KB
2025-05-08 05:00
Earnings Release
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 6.5 KB
2025-04-30 06:00
Report Publication Announcement
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
English 1.7 KB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 4.6 MB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
English 1.4 KB
2025-04-22 05:47
Regulatory News Service
Zelluna Reaches Major Milestone with Manufacturing Process Established in Prepa…
English 6.3 KB
2025-04-08 06:43
Report Publication Announcement
Financial calendar
English 681 bytes
2025-04-04 13:21
Director's Dealing
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary i…
English 86.5 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Antibiotice S.A. Logo
Manufactures FDA-approved generic drugs, sterile injectables, and APIs for global markets.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
Japan 4886
Astellas Pharma Inc. Logo Japan 4503
AstraZeneca PLC Logo
A global biopharma firm developing medicines for oncology, rare diseases, and biopharmaceuticals.
United Kingdom AZN
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland BANB